Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-Alcoholic Fatty Liver Disease.

Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-Alcoholic Fatty Liver Disease. Curr Pharm Biotechnol. 2019 Mar 11;: Authors: Kim JC, Jeon JY, Yang WS, Kim CH, Eom DW Abstract Red ginseng is a traditional medicine that has been used to treat numerous metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce NAFLD and liver inflammation compared with the effects reported for each individual product. db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively, and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein phosphorylation, and gene expression patterns. KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease in inflammatory cytokine secretion compared with the non-treated control mice. The same treatment was less successful in improving NAFLD parameters in the db/db mice while the combination of both products did not enhance their therapeutic potential. The results of this study indicate that KRG and probiotics administration ameliorated NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation. Coadm...
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research

Related Links:

This study was aimed at evaluating the intra-observer repeatability of shear wave dispersion imaging (SWDI) for evaluation of non-alcoholic fatty liver disease and assessing inter-observer repeatability in asymptomatic volunteers, using a commercial ultrasound system. This prospective study was approved by our institutional review board and informed consent was obtained from all patients. In group I composed of patients with suspected or alleged non-alcoholic fatty liver disease (n  = 71), two sessions of SWDI were performed by one radiologist for evaluation of intra-observer repeatability.
Source: Ultrasound in Medicine and Biology - Category: Radiology Authors: Tags: Original Contribution Source Type: research
.
Source: Journal of the American College of Nutrition - Category: Nutrition Authors: Source Type: research
ConclusionExperimental validation of network analysis revealed anti-diabetic effects of the plant product SGD, manifested most notably by improved serum profiles and diminished insulin resistance. These experimental results may have clinical implications.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
The identification of patients with advanced liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) remains challenging. Using non-invasive liver fibrosis tests (NILT) in primary care may permit...
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Research article Source Type: research
In this issue of Metabolism, Omori et al [1] report that dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), prevents hepatic steatosis (assessed by triglyceride liver content) after 8  weeks of administration in db/db mice, a mouse model of obesity and diabetes.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
Publication date: Available online 10 July 2019Source: Life SciencesAuthor(s): Yunxia Dong, Henglei Lu, Qiang Li, Xinming Qi, Yuanchao Li, Zean Zhang, Jing Chen, Jin RenAbstractAims(5R)-5-hydroxytriptolide (LLDT-8) is a triptolide analog with excellent capability against cancers, cerebral ischemic injury and rheumatoid arthritis. Here, we discovered its hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease (NAFLD) by ameliorating liver lipid accumulation.Main methodsMale C57BL/6J mice were fed with a high-fat/high-fructose (HFHFr) diet for 29 weeks to induce the pathological phenomena of NAFLD. T...
Source: Life Sciences - Category: Biology Source Type: research
In this study, the effects of AGE on fatty liver, insulin resistance and intestinal microbiota were compared between ddY-H mice, an insulin resistance mouse, and ddY-L mice, normal mice. Mice were fed an AGE-supplemented diet (4% w/w) for 7 weeks. The administration of AGE had no effect on the body weight and dietary intake of both types of mice. In the ddY-H mice, the serum levels of glucose and insulin were increased and glucose tolerance was impaired; however, the administration of AGE ameliorated these abnormal conditions. AGE did not have these effects in ddY-L mice. Triglyceride (TG) accumulation in the liver and fat...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
The recent epidemic in chronic liver disease is related to the burden of Non-Alcoholic Fatty Liver Disease (NAFLD), paralleling the worldwide increase of obesity. [1] NAFLD is a complex condition related to metabolic derangements in insulin resistance (IR), but in a subset of patients the liver becomes the target of multiple hits leading to Non-Alcoholic SteatoHepatitis (NASH), the histological phenotype that may progressively develop liver fibrosis, cirrhosis and possibly hepatocellular carcinoma.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
CONCLUSIONS: NAFLD was associated with rUTI in premenopausal women, independent of metabolic syndrome. Further studies are needed to confirm this association. PMID: 31280506 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
ConclusionsSMI level in patients with NAFLD was lower than healthy people, and patients with sarcopenia have higher occurrence risk of NAFLD, as well as its advanced stages including NASH or NAFLD-related significant fibrosis. Further well-designed prospective studies are required to strengthen the arguments.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Alcoholism | Biotechnology | Diets | Fatty Liver Disease (FLD) | Genetics | Ginseng | High Fat | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Probiotics | Study | Urology & Nephrology